Intravitreal injection (IVI) of an anti-vascular endothelial growth factor (VEGF) agent is the standard treatment for retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Here, VEGFA is linked to diabetic macular edema.